Effect of ischemic preconditioning on cardiovascular outcomes in patients with symptomatic coronary artery disease: a cohort study

Imagem de Miniatura
Arquivos
art_RAHMI_Effectof_ischemic_preconditioning_on_cardiovascular_outcomes_in_2019.PDF.pdf (167.65 KB)
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2019
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
LIPPINCOTT WILLIAMS & WILKINS
Autores
Citação
CORONARY ARTERY DISEASE, v.30, n.7, p.536-541, 2019
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background Despite the powerful myocardial protection of ischemic preconditioning (IP) observed in experimental studies, it remains a challenge to observe such protection in humans. Thus, the aim of this study was to evaluate the possible effects of IP on clinical outcomes in patients with coronary artery disease (CAD). Patients and methods In this cohort study, patients with multivessel CAD, preserved systolic ventricular function, and stable angina were prospectively selected. They underwent two sequential exercise stress tests (EST) to evaluate IP presence. IP was considered present if patients had an improvement in the time to the onset of 1.0-mm STsegment deviation in the second EST. The primary end point was the composite rate of cardiac death, nonfatal myocardial infarction, or revascularization during 1-year follow-up. Patients with (IP+) and without (IP-) the cardioprotective mechanism were compared regarding clinical end points. Results A total of 229 patients completed EST and had IP evaluated: 165 (72%) were IP+ and 64 (28%) were IP - patients. Of these, 218 patients had complete follow-up. At 1-year, event-free survival regarding the primary end point was 95.5 versus 83.6% (P = 0.0024) and event-free survival regarding cardiac death or myocardial infarction was 99.4 versus 91.7% (P=0.0020), respectively, in IP + and IP - groups. The unadjusted hazard ratio (IP + /IP-) for the primary end point was 4.63 (1.52-14.08). After multivariate analysis, IP was still significantly associated with better clinical outcomes (P = 0.0025). Conclusion This data suggest that IP may contribute to better clinical outcomes in patients with ischemic heart disease.
Palavras-chave
coronary artery disease, ischemic preconditioning, myocardial infarction, myocardial ischemia
URI
https://observatorio.fm.usp.br/handle/OPI/35419
Referências
  1. Bilinska M, 2007, CORONARY ARTERY DIS, V18, P455, DOI 10.1097/MCA.0b013e3282a30676
  2. Clarke SJ, 2014, CARDIOVASC DIABETOL, V13, DOI 10.1186/1475-2840-13-12
  3. CRIBIER A, 1992, J AM COLL CARDIOL, V20, P578, DOI 10.1016/0735-1097(92)90011-B
  4. DEUTSCH E, 1990, CIRCULATION, V82, P2044, DOI 10.1161/01.CIR.82.6.2044
  5. Ebrahim Z, 2004, CARDIOVASC DRUG THER, V18, P127, DOI 10.1023/B:CARD.0000029030.49492.5a
  6. Eltchaninoff H, 1997, AM HEART J, V133, P490, DOI 10.1016/S0002-8703(97)70200-X
  7. Ferdinandy P, 2014, PHARMACOL REV, V66, P1142, DOI 10.1124/pr.113.008300
  8. Fryer RM, 2002, CARDIOVASC RES, V55, P520, DOI 10.1016/S0008-6363(02)00316-4
  9. HARKEN AH, 1981, AM J PHYSIOL, V241, pH202
  10. Ishihara M, 2001, J AM COLL CARDIOL, V38, P1007, DOI 10.1016/S0735-1097(01)01477-2
  11. KLONER RA, 1995, CIRCULATION, V91, P37, DOI 10.1161/01.CIR.91.1.37
  12. Laskey WK, 1999, CIRCULATION, V99, P2085, DOI 10.1161/01.CIR.99.16.2085
  13. Lee TM, 2003, J CLIN ENDOCR METAB, V88, P531, DOI 10.1210/jc.2002-020904
  14. Miki T, 1996, J AM COLL CARDIOL, V28, P1616, DOI 10.1016/S0735-1097(96)00371-3
  15. MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124
  16. OKAZAKI Y, 1993, J AM COLL CARDIOL, V21, P1597, DOI 10.1016/0735-1097(93)90374-A
  17. Okishige K, 1996, J AM COLL CARDIOL, V28, P70, DOI 10.1016/0735-1097(96)00119-2
  18. Rahmi RM, 2013, DIABETES CARE, V36, P1654, DOI 10.2337/dc12-1495
  19. Rezende PC, 2015, CARDIOVASC DIABETOL, V14, DOI 10.1186/s12933-015-0228-x
  20. Rezende PC, 2013, BMC CARDIOVASC DISOR, V13, DOI 10.1186/1471-2261-13-117
  21. Roglic G, 2005, DIABETES CARE, V28, P2130, DOI 10.2337/diacare.28.9.2130
  22. SCHOTT RJ, 1990, CIRC RES, V66, P1133, DOI 10.1161/01.RES.66.4.1133
  23. Tamura K, 1997, AM HEART J, V133, P297, DOI 10.1016/S0002-8703(97)70223-0
  24. THORNTON J, 1990, AM J PHYSIOL, V259, pH1822
  25. Van der Mieren G, 2013, CARDIOVASC DIABETOL, V12, DOI 10.1186/1475-2840-12-36
  26. Walsh SR, 2008, EUR J CARDIO-THORAC, V34, P985, DOI 10.1016/j.ejcts.2008.07.062
  27. Yang XL, 2010, CARDIOVASC DRUG THER, V24, P225, DOI 10.1007/s10557-010-6236-x
  28. YELLON DM, 1992, CARDIOVASC RES, V26, P983, DOI 10.1093/cvr/26.10.983

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCP
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - LIM/11
Artigos e Materiais de Revistas Científicas - ODS/03